Gene · 2696
Papers1,380
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
1 to 20 of 1,380
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Genetically Proxied GIP-GIPR Pathway Perturbation and Fracture Risk. | Diabetes Obes Metab | 2026 | 42811415 | PubTator, text mining | PubMed |
| Skeletal Muscle Effects of GLP 1 Receptor Agonists: Molecular Mechanisms and Comparative Insights on Semaglutide and Tirzepatide, a Narrative Review. | Int J Mol Sci | 2026 | 42794486 | PubTator, text mining | PubMed |
| Genetic Assessment of Oesophageal Safety of GLP-1 and GIP Receptor Perturbation: A Drug-Target Mendelian Randomisation Study. | Biomedicines | 2026 | 42792631 | PubTator, text mining | PubMed |
| Genome-wide mapping of common and rare variant effects on adiposity across childhood. | Nat Genet | 2026 | 42791368 | PubTator, text mining | PubMed |
| Pulsatile liraglutide on a biased tirzepatide background: a hypothesis. | Front Endocrinol (Lausanne) | 2026 | 42787169 | PubTator, text mining | PubMed |
| GLP-1 receptor agonists and podocyte senescence in diabetic kidney disease: structural pharmacology, mechanistic evidence, and multi-receptor agonism. | Biochem Pharmacol | 2026 | 42777788 | PubTator, text mining | PubMed |
| AGA Clinical Practice Update on the Evaluation and Management of Metabolic Dysfunction- and Alcohol-Associated Liver Disease: Expert Review. | Clin Gastroenterol Hepatol | 2026 | 42776095 | PubTator, text mining | PubMed |
| The incretin-joint axis: weight-independent mechanisms and disease-modifying potential in chronic arthropathies. | Rheumatol Adv Pract | 2026 | 42774139 | PubTator, text mining | PubMed |
Effectiveness, Safety and Pharmacokinetics of BGM0504, a Dual GLP-1/GIP Receptor Agonist, in Chinese Adults With Overweight or Obesity Without Diabetes: A Phase 2 Multicentre, Randomized, Double-Blind, Placebo-Controlled Trial. | Diabetes Obes Metab | 2026 | 42755112 | PubTator, text mining | PubMed |
| Redefining weight management after liver transplantation with glucagon-like peptide one and gastric inhibitory polypeptide receptor agonists. | World J Transplant | 2026 | 42751234 | PubTator, text mining | PubMed |
| Detection and Excretion Profile of Retatrutide in Human Plasma and Urine by LC-HRMS: Implications for Antidoping Analysis. | Rapid Commun Mass Spectrom | 2026 | 42745421 | PubTator, text mining | PubMed |
| GLP-1 Receptor Agonist and GIP/GLP-1 Receptor Dual Agonist Therapeutics at the Intersection of Alcohol Use Disorder, Obesity, and Cardiometabolic Dysfunction. | Biol Psychiatry Glob Open Sci | 2026 | 42741173 | PubTator, text mining | PubMed |
| Structural basis for small-molecule agonism at GCGR and GIPR via a conserved intracellular allosteric site. | Acta Pharmacol Sin | 2026 | 42736455 | PubTator, text mining | PubMed |
| Comparative outcomes for tirzepatide versus glucagon-like peptide-1 receptor agonists in patients with inflammatory bowel disease: a national propensity matched study. | Intest Res | 2026 | 42717572 | PubTator, text mining | PubMed |
| Glycemic and bodyweight effects of GIPR coding variation reflect differences in surface expression and intrinsic functional impairment. | Sci Adv | 2026 | 42696562 | PubTator, text mining | PubMed |
Genetically proxied glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide receptor pathway modulation is associated with favorable aging phenotypes: a drug-target Mendelian randomization study. | Cardiovasc Diabetol | 2026 | 42642762 | PubTator, text mining | PubMed |
| Responders Vs. Non-Responders or How to Predict the Response to GLP-1 or GLP-1/GIP Receptor Agonist Therapy. | Diabetes Obes Metab | 2026 | 42634284 | PubTator, text mining | PubMed |
| Appetite-suppressing effects of GIPR agonism and antagonism work through different brain regions. | Nat Rev Endocrinol | 2026 | 42618736 | PubTator, text mining | PubMed |
| Role of glucagon in metabolic diseases. | J Diabetes Investig | 2026 | 42593182 | PubTator, text mining | PubMed |
| Design and therapeutic rationale of antibody-peptide conjugates: insights from maridebart cafraglutide (AMG133) and emerging applications. | Antib Ther | 2026 | 42592044 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/2696/papers